CLAIMS

1. A crystalline form of 2-((2S,3S,4S)-5-Chloro-6-fluoro-3-methyl-2-((methylamino)methyl)-2-phenyl-2,3-dihydrobenzofuran-4-yl)-3-fluoro-4-methoxybenzamide (**Compound B**) or pharmaceutically acceptable solvate and/or salt thereof.

2. A crystalline form of 4-((2S,4S)-5-Chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide (**Compound A**) or pharmaceutically acceptable solvate and/or salt thereof.

3. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a succinate salt.

4. The crystalline form according to claim 3, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. all 13 2θ values) selected from the group consisting of:

Angle (2θ)
11.93° ±0.2°
13.26° ±0.2°
13.77° ±0.2°
15.12° ±0.2°
16.99° ±0.2°
17.39° ±0.2°
19.92° ±0.2°
20.73° ±0.2°
21.06° ±0.2°
23.45° ±0.2°
24.11° ±0.2°
26.37° ±0.2°
26.66° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern

comprises at least the peaks at 13.26° ±0.2°, 16.99° ±0.2°, 19.92° ±0.2° and 26.66° ±0.2°.

5. The crystalline form according to claim 3 or claim 4, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 1, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

6. The crystalline form according to any one of claims 3 to 5, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 2.

7. The crystalline form according to any one of claims 3 to 6, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 3.

8. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a malate salt.

9. The crystalline form according to claim 8, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. 13 or more, e.g. all 14 2θ values) selected from the group consisting of:

Angle (2θ)
12.28° ±0.2°
13.13° ±0.2°
13.86° ±0.2°
15.04° ±0.2°
15.88° ±0.2°
16.91° ±0.2°
17.52° ±0.2°
19.63° ±0.2°
20.49° ±0.2°
21.24° ±0.2°

23.52° ±0.2°
26.26° ±0.2°
26.61° ±0.2°
27.76° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 13.86° ±0.2°, 16.91° ±0.2°, 19.63° ±0.2° and 23.52° ±0.2°.

10. The crystalline form according to claim 8 or claim 9, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 4, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

11. The crystalline form according to any one of claims 8 to 10, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 5.

12. The crystalline form according to any one of claims 8 to 11, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 6.

13. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a lactate salt.

14. The crystalline form according to claim 13, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. all 13 2θ values) selected from the group consisting of:

Angle (2θ)
10.50° ±0.2°
13.37° ±0.2°
14.62° ±0.2°

16.13° ±0.2°
16.62° ±0.2°
18.07° ±0.2°
21.25° ±0.2°
22.41° ±0.2°
22.63° ±0.2°
22.76° ±0.2°
23.79° ±0.2°
26.84° ±0.2°
30.91° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 10.50° ±0.2°, 13.37° ±0.2°, 18.07° ±0.2° and 22.41° ±0.2°.

15. The crystalline form according to claim 13 or claim 14, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 7, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

16. The crystalline form according to any one of claims 13 to 15, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 8.

17. The crystalline form according to any one of claims 13 to 16, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 9.

18. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a benzoate salt.

19. The crystalline form according to claim 18, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6

or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. all 13 2θ values) selected from the group consisting of:

Angle (2θ)
5.47° ±0.2°
8.71° ±0.2°
10.30° ±0.2°
10.92° ±0.2°
12.01° ±0.2°
12.24° ±0.2°
13.79° ±0.2°
14.51° ±0.2°
20.50° ±0.2°
21.87° ±0.2°
23.23° ±0.2°
29.19° ±0.2°
31.06° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 5.47° ±0.2°, 10.92° ±0.2°, 12.24° ±0.2° and 21.87° ±0.2°.

20. The crystalline form according to claim 18 or claim 19, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 10, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

21. The crystalline form according to any one of claims 18 to 20, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 11.

22. The crystalline form according to any one of claims 18 to 21, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 12.

23. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a glutamate salt.

24. The crystalline form according to claim 23, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. all 11 2θ values) selected from the group consisting of:

Angle (2θ)
13.33° ±0.2°
13.77° ±0.2°
14.96° ±0.2°
18.02° ±0.2°
18.40° ±0.2°
20.02° ±0.2°
21.15° ±0.2°
23.69° ±0.2°
24.02° ±0.2°
24.79° ±0.2°
26.77° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 13.33° ±0.2°, 14.96° ±0.2°, 20.02° ±0.2° and 26.77° ±0.2°.

25. The crystalline form according to claim 23 or claim 24, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 13, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

26. The crystalline form according to any one of claims 23 to 25, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 14.

27. The crystalline form according to any one of claims 23 to 26, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 15.

28. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a maleate salt.

29. The crystalline form according to claim 28, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. all 12 2θ values) selected from the group consisting of:

Angle (2θ)
12.80° ±0.2°
14.22° ±0.2°
14.57° ±0.2°
15.35° ±0.2°
16.11° ±0.2°
17.71° ±0.2°
21.38° ±0.2°
22.92° ±0.2°
23.88° ±0.2°
24.39° ±0.2°
25.51° ±0.2°
28.61° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 12.80° ±0.2°, 14.57° ±0.2°, 16.11° ±0.2° and 17.71° ±0.2°.

30. The crystalline form according to claim 28 or claim 29, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 16, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

31. The crystalline form according to any one of claims 28 to 30, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 17.

32. The crystalline form according to any one of claims 28 to 31, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 18.

33. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a malonate salt.

34. The crystalline form according to claim 33, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. all 13 2θ values) selected from the group consisting of:

Angle (2θ)
9.68° ±0.2°
13.90° ±0.2°
14.31° ±0.2°
15.20° ±0.2°
17.28° ±0.2°
18.29° ±0.2°
21.20° ±0.2°
21.94° ±0.2°
22.23° ±0.2°
23.63° ±0.2°
24.07° ±0.2°
28.07° ±0.2°
29.17° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 9.68° ±0.2°, 13.90° ±0.2°, 21.20° ±0.2° and 21.94° ±0.2°.

35. The crystalline form according to claim 33 or claim 34, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 19, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

36. The crystalline form according to any one of claims 33 to 35, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 20.

37. The crystalline form according to any one of claims 33 to 36, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 21.

38. The crystalline form according to claim 33, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. all 13 2θ values) selected from the group consisting of:

Angle (2θ)
12.25° ±0.2°
14.01° ±0.2°
17.23° ±0.2°
17.59° ±0.2°
17.91° ±0.2°
19.28° ±0.2°
20.55° ±0.2°
22.53° ±0.2°
22.89° ±0.2°
23.42° ±0.2°
24.08° ±0.2°
24.59° ±0.2°
27.45° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 12.25° ±0.2°, 17.91° ±0.2°, 19.28° ±0.2° and 24.08° ±0.2°.

39. The crystalline form according to claim 33 or claim 38, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 22, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

40. The crystalline form according to any one of claims 33, 38 and 39, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 23.

41. The crystalline form according to any one of claims 33 and 38 to 40, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 24.

42. The crystalline form according to claim 1, wherein the **Compound B** is in the form of a mesylate salt.

43. The crystalline form according to claim 42, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. all 13 2θ values) selected from the group consisting of:

Angle (2θ)
12.99° ±0.2°
13.76° ±0.2°
15.78° ±0.2°
16.46° ±0.2°
16.91° ±0.2°
17.42° ±0.2°
18.18° ±0.2°
18.99° ±0.2°
20.40° ±0.2°
21.13° ±0.2°
22.42° ±0.2°
23.32° ±0.2°
23.57° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 13.76° ±0.2°, 15.78° ±0.2°, 16.46° ±0.2° and 18.18° ±0.2°.

44. The crystalline form according to claim 42 or claim 43, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as

shown in FIG. 25, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

45. The crystalline form according to any one of claims 42 to 44, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 26.

46. The crystalline form according to any one of claims 42 to 45, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 27.

47. The crystalline form according to claim 1, wherein the **Compound B** is in free form.

48. The crystalline form according to claim 47, wherein the **Compound B** is in the form of **Compound B** free form 2-methyl-2-butanol solvate

49. The crystalline form according to claim 47 or claim 48, characterized by an X-ray powder diffraction pattern comprising peaks at four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. 11 or more, e.g. 12 or more, e.g. all 13 2θ values) selected from the group consisting of:

Angle (2θ)
5.58° ±0.2°
7.44° ±0.2°
9.66° ±0.2°
10.85° ±0.2°
11.31° ±0.2°
13.79° ±0.2°
14.76° ±0.2°
15.56° ±0.2°
17.76° ±0.2°
19.44° ±0.2°
22.42° ±0.2°
25.71° ±0.2°
26.18° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 5.58° ±0.2°, 9.66° ±0.2°, 15.56° ±0.2° and 19.44° ±0.2°.

50. The crystalline form according to any one of claims 47 to 49, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 28, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

51. The crystalline form according to any one of claims 47 to 50, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 29.

52. The crystalline form according to any one of claims 47 to 51, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 30.

53. The crystalline form according to claim 2, wherein the **Compound A** is free form **Compound A** or a solvate thereof.

54. The crystalline form according to claim 53, characterized by an X-ray powder diffraction pattern comprising four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. all ten 2θ values) selected from the group consisting of:

Angle
7.00 ° ±0.2°
9.21 ° ±0.2°
10.98 ° ±0.2°
16.06 ° ±0.2°
17.24 ° ±0.2°
17.82 ° ±0.2°
19.25 ° ±0.2°
21.80 ° ±0.2°

22.84 ° ±0.2°
24.69 ° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 7.00° ±0.2°, 9.21° ±0.2°, 10.98° ±0.2° and 21.80° ±0.2°.

55. The crystalline form according to claim 53 or claim 54, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 31, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

56. The crystalline form according to any one of claims 53 to 55, wherein the **Compound A** is a solvate of free form **Compound A**.

57. The crystalline form according to any one of claims 53 to 56, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 32.

58. The crystalline form according to any one of claims 53 to 57, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 33.

59. The crystalline form according to claim 2, wherein the **Compound A** is in the form of a 4-hydroxybenzoate salt.

60. The crystalline form according to claim 59, characterized by an X-ray powder diffraction pattern comprising four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. 10 or more, e.g. all 11 2θ values) selected from the group consisting of:

Angle
9.28 ° ±0.2°
10.98 ° ±0.2°
11.78 ° ±0.2°
15.00 ° ±0.2°
15.71 ° ±0.2°
16.79 ° ±0.2°
18.57 ° ±0.2°
20.00 ° ±0.2°
22.02 ° ±0.2°
24.09 ° ±0.2°
24.98 ° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 10.98° ±0.2°, 11.78° ±0.2°, 16.79° ±0.2° and 20.00° ±0.2°.

61. The crystalline form according to claim 59 or claim 60, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 34, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

62. The crystalline form according to any one of claims 59 to 61, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 35.

63. The crystalline form according to any one of claims 59 to 62, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 36.

64. The crystalline form according to claim 2, wherein the **Compound A** is in the form of a 3,4-dihydroxybenzoate salt.

65. The crystalline form according to claim 64, characterized by an X-ray powder diffraction pattern comprising four or more 2θ values (e.g. 5 or more, e.g. 6 or more, e.g. 7 or more, e.g. 8 or more, e.g. 9 or more, e.g. all 10 2θ values) selected from the group consisting of:

Angle
10.48 ° ±0.2°
11.75 ° ±0.2°
14.62 ° ±0.2°
14.79 ° ±0.2°
15.16 ° ±0.2°
16.27 ° ±0.2°
19.04 ° ±0.2°
19.70 ° ±0.2°
23.41 ° ±0.2°
24.18 ° ±0.2°

wherein the temperature is about room temperature and the radiation used has a wavelength of 1.54060Å, and preferably wherein the X-ray powder diffraction pattern comprises at least the peaks at 10.48° ±0.2°, about 11.75° ±0.2°, 16.27° ±0.2° and 19.70° ±0.2°.

66. The crystalline form according to claim 64 or claim 65, having an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction spectrum as shown in FIG. 37, at about room temperature wherein the radiation used has a wavelength of 1.54060 Å.

67. The crystalline form according to any one of claims 64 to 66, having a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 38.

68. The crystalline form according to any one of claims 64 to 67, having a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 39.

69. A pharmaceutical composition comprising the crystalline form of any one of the preceding claims and a pharmaceutically acceptable carrier.

70. The crystalline form according to any one of claims 1 to 68, or the pharmaceutical composition according to claim 69 for use as a medicament.

71. A combination comprising a crystalline form of any of claims 1 to 68 and one or more therapeutically active agents.

72. Use of a crystalline form according to any one of claims 1 to 68; or a pharmaceutical composition according to claim 69; or a combination according to claim 71 in the manufacture of a medicament for the treatment of a disease or condition mediated by YAP overexpression and/or YAP amplification and/or YAP/TAZ-TEAD interaction, or a method of treating a cancer or tumor harboring (i) one or more YAP/TAZ fusions; (ii) one or more NF2/LATS1/LATS2 truncating mutations or deletions; or (iii) one or more functional YAP/TAZ fusions, wherein a therapeutically effective amount of the medicament is to be administered to a subject in need thereof.

73. The use according to claim 72, wherein the cancer is selected from a cancer or tumor which is selected from mesothelioma (including pleural mesothelioma, malignant pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma and mesothelioma of the tunica vaginalis), carcinoma (including cervical squamous cell carcinoma, endometrial carcinoma, esophageal squamous cell carcinoma, esophageal adenocarcinoma, urothelial carcinoma of the bladder and squamous cell carcinoma of the skin), poroma (benign poroma), porocarcinoma (including malignant porocarcinoma), supratentorial ependymoma (including childhood supratentorial ependymoma), epithelioid hemangioendothelioma (EHE), ependymal tumor, a solid tumor, breast cancer (including triple negative breast cancer), lung cancer (including non-small cell lung cancer), ovarian cancer, colorectal cancer (including colorectal

carcinoma), melanoma, pancreatic cancer (including pancreatic adenocarcinoma), prostate cancer, gastric cancer, esophageal cancer, liver cancer (including hepatocellular carcinoma, cholangiocarcinoma and hepatoblastoma), neuroblastoma, Schwannoma, kidney cancer, sarcoma (including rhabdomyosarcoma, embryonic rhabdomyosarcoma (ERMS), osteosarcoma, undifferentiated pleomorphic sarcomas (UPS), Kaposi's sarcoma, soft-tissue sarcoma and rare soft-tissue sarcoma), bone cancer, brain cancer, medulloblastoma, glioma, meningioma, and head and neck cancer (including head and neck squamous cell carcinoma).